Sesen Bio, Inc. on February 20, 2020, announced the appointment of Carrie Bourdow, chief executive officer of Trevena, Inc., and Jason Keyes, chief financial officer of Equillium, to the company’s Board of Directors. Ms. Bourdow was designated as a Class I member of the Board to serve until the 2021 annual meeting of the stockholders of the company and thereafter until her successor has been duly elected and qualified, or until her earlier death, resignation or removal. Ms. Bourdow has been appointed as a member of the Nominating and Corporate Governance Committee of the Board. Mr. Keyes was designated as a Class II member of the Board to serve until the 2022 annual meeting of the stockholders of the company and thereafter until his successor has been duly elected and qualified, or until his earlier death, resignation or removal. Mr. Keyes has been appointed as a member of the Audit Committee of the Board. In addition, Wendy L. Dixon, Ph.D., has resigned from her position as chairwoman of the Board and member of the Board effective February 20, 2020. Wendy resigned from the Board as a Class II director effective February 24, 2020. Dr. Dixon will continue to serve as a CEO advisor to Sesen Bio with a focus on commercial and launch planning. The Board has appointed Dr. Jay Duker, chairman of Ophthalmology at Tufts Medical Center and co-founder of Hemera Biosciences, to succeed Dr. Dixon as chair. Dr. Duker has served on the Board since 2015. With the appointments of Ms. Bourdow and Mr. Keyes, and the resignation of Dr. Dixon, the company’s Board will be comprised of six directors of which five are independent. Dr. Dixon brought more than 35 years of biopharmaceutical, commercial and R&D leadership experience to Sesen Bio. As a well-respected senior executive, Dr. Dixon played an integral role in the evolution of Sesen Bio from a development company to a company with significant growth aspirations moving into the pre-commercial phase. Leveraging her extensive experience across commercial and development, including her role as chief marketing officer and president of global marketing of Bristol-Myers Squibb, Dr. Dixon has helped position the company for success as it advances toward commercialization. Ms. Bourdow brings significant experience in product launch and commercial operations in specialty care across multiple therapeutic areas, including leadership experience in key products in the oncology space. Ms. Bourdow currently serves as chief executive officer of Trevena. Prior to her role as chief executive officer, Ms. Bourdow joined Trevena as chief commercial officer in 2015 and was appointed executive vice president and chief operating officer in January 2018. Prior to joining Trevena, Ms. Bourdow was vice president of marketing at Cubist Pharmaceuticals, Inc., from 2013 until its acquisition by Merck & Co., Inc. in January 2015. At Cubist, Ms. Bourdow led launch strategy, marketing, reimbursement, and operations for products totaling over $1 billion in annual revenues. Prior to Cubist, Ms. Bourdow served for more than 20 years at Merck & Co., Inc., where she held positions of increasing responsibility across commercial functions and therapeutic areas. Since June 2017, she has served on the board of Nabriva Therapeutics plc. Mr. Keyes is an accomplished executive with extensive experience in corporate finance and strategy within the biotechnology industry. Mr. Keyes currently serves as chief financial officer of Equillium. Prior to joining Equillium, he was executive vice president and chief financial officer of Orexigen Therapeutics, Inc. where he played a key role in setting the business and financial strategy for the global commercialization of the product portfolio. Prior to Orexigen, Mr. Keyes was Senior Director of Finance at Amylin Pharmaceuticals, Inc. until its acquisition by Bristol Myers-Squibb Company. Earlier in his career, Mr. Keyes held leadership positions in finance and corporate strategy at Amgen, Inc. and Baxter Healthcare Corporation. Over his career, Mr. Keyes has been responsible for leading financial planning across the biotechnology value chain, managing investor relations, raising capital, and driving business development.